Balancing benefit and risk of medicines: a systematic review and classification of available methodologies
暂无分享,去创建一个
L. Phillips | I. Tzoulaki | D. Ashby | N. Wang | C. E. Hallgreen | S. Hobbiger | S. Mt-Isa | Kimberley Hockley | G. Genov | A. Micaleff | T. Callréus | I. Hirsch | D. Luciani | G. Quartey | S. Sarac | Isabelle Stoeckert | Nan Wang | I. Stoeckert | Georgy Genov | Christine E. Hallgreen
[1] Ortwin Renn,et al. A Decision‐Analysis Tool for Benefit–Risk Assessment of Nonprescription Drugs , 2013, Journal of clinical pharmacology.
[2] Tommi Tervonen,et al. ADDIS: A decision support system for evidence-based medicine , 2013, Decis. Support Syst..
[3] James J. Chen,et al. Quantitative Benefit-Risk Analysis for Evaluating Drug Therapies , 2013, Journal of biopharmaceutical statistics.
[4] R. Varadhan,et al. A framework for organizing and selecting quantitative approaches for benefit-harm assessment , 2012, BMC Medical Research Methodology.
[5] Andy Hart,et al. BRAFO tiered approach for Benefit-Risk Assessment of Foods. , 2012, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[6] R. Varadhan,et al. Methods for Benefit and Harm Assessment in Systematic Reviews , 2012 .
[7] Rosalee S. Hellberg,et al. Risk-Benefit Analysis of Seafood Consumption: A Review , 2012 .
[8] Erik Mosekilde,et al. A Comprehensive Approach to Benefit–Risk Assessment in Drug Development , 2012, Basic & clinical pharmacology & toxicology.
[9] Tommi Tervonen,et al. Multicriteria benefit-risk assessment using network meta-analysis. , 2012, Journal of clinical epidemiology.
[10] I. Buchan,et al. Population Impact Analysis: a framework for assessing the population impact of a risk or intervention. , 2012, Journal of public health.
[11] S. Walker,et al. Standardizing the Benefit-Risk Assessment of New Medicines , 2011, Pharmaceutical Medicine.
[12] N. Kalogeras,et al. State of the art in benefit-risk analysis: food microbiology. , 2012, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[13] Jixian Wang,et al. Statistical aspects in comparative benefit‐risk assessment: challenges and opportunities for pharmaceutical statisticians , 2012, Pharmaceutical statistics.
[14] M. Morelle,et al. Cancer patients’ willingness to pay for blood transfusions at home: results from a contingent valuation study in a French cancer network , 2012, The European Journal of Health Economics.
[15] Ortwin Renn,et al. Improving the Decision‐Making Process for Nonprescription Drugs: A Framework for Benefit–Risk Assessment , 2011, Clinical pharmacology and therapeutics.
[16] A. Sashegyi. A Benefit-risk Model to Facilitate DMC-sponsor Communication and Decision Making , 2011 .
[17] P. Schulz,et al. Assessing the benefit:risk ratio of a drug - randomized and naturalistic evidence , 2011, Dialogues in clinical neuroscience.
[18] Tommi Tervonen,et al. A stochastic multicriteria model for evidence‐based decision making in drug benefit‐risk analysis , 2011, Statistics in medicine.
[19] Shahrul Mt-Isa,et al. Weighing benefit-risk of medicines: concepts and approaches. , 2011, Drug discovery today. Technologies.
[20] B S Levitan,et al. Development of a Framework for Enhancing the Transparency, Reproducibility and Communication of the Benefit–Risk Balance of Medicines , 2011, Clinical pharmacology and therapeutics.
[21] B S Levitan,et al. Application of the BRAT Framework to Case Studies: Observations and Insights , 2011, Clinical pharmacology and therapeutics.
[22] Lawrence D. Phillips,et al. Benefit-risk methodology project: work package 2 report: applicability of current tools and processes for regulatory benefit-risk assessment , 2011 .
[23] Mohsen Sadatsafavi,et al. A quantitative evaluation of the regulatory assessment of the benefits and risks of rofecoxib relative to naproxen: an application of the incremental net‐benefit framework , 2010, Pharmacoepidemiology and drug safety.
[24] John Doyle,et al. A review of quantitative risk-benefit methodologies for assessing drug safety and efficacy-report of the ISPOR risk-benefit management working group. , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[25] A first step to assess harm and benefit in clinical trials in one scale. , 2010, Journal of clinical epidemiology.
[26] Mark J Sculpher,et al. Using the incremental net benefit framework for quantitative benefit-risk analysis in regulatory decision-making--a case study of alosetron in irritable bowel syndrome. , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[27] An effective process for making decisions about major operating room purchases. , 2010, AORN journal.
[28] D. Ouellet. Benefit–risk assessment: the use of clinical utility index , 2010, Expert opinion on drug safety.
[29] L. Citrome. Relative vs. absolute measures of benefit and risk: what’s the difference? , 2010, Acta psychiatrica Scandinavica.
[30] J. Louviere,et al. Discrete Choice Experiments Are Not Conjoint Analysis , 2010 .
[31] Net efficacy adjusted for risk: further developments , 2009, Expert opinion on drug safety.
[32] L Liberti,et al. Measuring Benefit and Balancing Risk: Strategies for the Benefit–Risk Assessment of New Medicines in a Risk‐Averse Environment , 2009, Clinical pharmacology and therapeutics.
[33] J. Werth,et al. The Use of a Clinical Utility Index to Compare Insomnia Compounds: A Quantitative Basis for Benefit–Risk Assessment , 2009, Clinical pharmacology and therapeutics.
[34] F Reed Johnson,et al. Are Adult Patients More Tolerant of Treatment Risks Than Parents of Juvenile Patients? , 2009, Risk Analysis.
[35] L. Phillips,et al. Multi-criteria analysis: a manual , 2009 .
[36] Rajesh Krishna,et al. The Use of Clinical Utility Assessments in Early Clinical Development , 2009, The AAPS Journal.
[37] Sam Salek,et al. Benefit-Risk Appraisal of Medicines , 2008 .
[38] M. García-Sáiz,et al. Net Efficacy Adjusted for Risk (NEAR): A Simple Procedure for Measuring Risk:Benefit Balance , 2008, PloS one.
[39] E. Dorsey,et al. Quantitative risk-benefit analysis of natalizumab , 2008, Neurology.
[40] Christy Chuang-Stein,et al. Measures for Conducting Comparative Benefit: Risk Assessment , 2008 .
[41] I Persson,et al. What is the harm-benefit ratio of Cox-2 inhibitors? , 2008, International journal of epidemiology.
[42] C. Dewa,et al. A Clinician's Guide to Correct Cost-Effectiveness Analysis: Think Incremental Not Average , 2008, Canadian journal of psychiatry. Revue canadienne de psychiatrie.
[43] Mandy Ryan,et al. Using discrete choice experiments to value health and health care , 2008 .
[44] Lakhmi C. Jain,et al. Introduction to Bayesian Networks , 2008 .
[45] J. Figueira,et al. A survey on stochastic multicriteria acceptability analysis methods , 2008 .
[46] Sam Salek,et al. A quantitative approach to benefit‐risk assessment of medicines – part 1: the development of a new model using multi‐criteria decision analysis , 2007, Pharmacoepidemiology and drug safety.
[47] Louis P Garrison,et al. Assessing a structured, quantitative health outcomes approach to drug risk-benefit analysis. , 2007, Health affairs.
[48] A. Brennan,et al. PAR15 USING MIXED TREATMENT COMPARISONS AND METAREGRESSION TO PERFORM INDIRECT COMPARISONS TO ESTIMATE THE EFFICACY OF BIOLOGIC TREATMENTS IN RHEUMATOID ARTHRITIS , 2007 .
[49] E Ferguson,et al. From comparative risk assessment to multi-criteria decision analysis and adaptive management: recent developments and applications. , 2006, Environment international.
[50] F. Sassi. Calculating QALYs, comparing QALY and DALY calculations. , 2006, Health policy and planning.
[51] Alex J. Sutton,et al. Multiparameter evidence synthesis in epidemiology and medical decision‐making: current approaches , 2006 .
[52] J.,et al. Markov Models in Medical Decision Making : A Practical Guide , 2006 .
[53] K. Rich,et al. A review of economic tools for the assessment of animal disease outbreaks. , 2005, Revue scientifique et technique.
[54] Linda S. Deal,et al. Age-Specific Questionnaires Distinguish GERD Symptom Frequency and Severity in Infants and Young Children: Development and Initial Validation , 2005, Journal of pediatric gastroenterology and nutrition.
[55] M. A. Best. Bayesian Approaches to Clinical Trials and Health‐Care Evaluation , 2005 .
[56] Nicola J Cooper,et al. A Bayesian approach to evaluating net clinical benefit allowed for parameter uncertainty. , 2005, Journal of clinical epidemiology.
[57] G. Lu,et al. Combination of direct and indirect evidence in mixed treatment comparisons , 2004, Statistics in medicine.
[58] Larry D Lynd,et al. Advances in risk-benefit evaluation using probabilistic simulation methods: an application to the prophylaxis of deep vein thrombosis. , 2004, Journal of clinical epidemiology.
[59] Nicola J Cooper,et al. Benefits and harms associated with hormone replacement therapy: clinical decision analysis , 2004, BMJ : British Medical Journal.
[60] E M Faustman,et al. Comparative Risk and Policy Analysis in Environmental Health , 2003, Risk analysis : an official publication of the Society for Risk Analysis.
[61] Juhaeri Juhaeri,et al. Benefit‐risk analysis: examples using quantitative methods , 2003, Pharmacoepidemiology and drug safety.
[62] I. Buchan,et al. Communicating risks at the population level: application of population impact numbers , 2003, BMJ : British Medical Journal.
[63] Juhaeri Juhaeri,et al. Benefit‐risk analysis: a proposal using quantitative methods , 2003, Pharmacoepidemiology and drug safety.
[64] Richard D. Smith. Construction of the contingent valuation market in health care: a critical assessment. , 2003, Health economics.
[65] Y. Shih. Bayesian approach in pharmacoeconomics: relevance to decision-makers , 2003, Expert review of pharmacoeconomics & outcomes research.
[66] Anne Whitehead,et al. An illustration of the modelling of cost and efficacy data from a clinical trial , 2003, Statistics in medicine.
[67] T. Lumley. Network meta‐analysis for indirect treatment comparisons , 2002, Statistics in medicine.
[68] A. Dobson,et al. Impact numbers in health policy decisions , 2002, Journal of epidemiology and community health.
[69] A. Dobson,et al. Impact numbers: measures of risk factor impact on the whole population from case-control and cohort studies , 2002, Journal of epidemiology and community health.
[70] T J Ulahannan,et al. Decision Making in Health and Medicine: Integrating Evidence and Values , 2002 .
[71] Christopher J Cates,et al. Simpson's paradox and calculation of number needed to treat from meta-analysis , 2002, BMC medical research methodology.
[72] Andrew H Briggs,et al. Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies. , 2002, Annual review of public health.
[73] A Ludbrook,et al. Use of discrete choice experiments to elicit preferences , 2001, Quality in health care : QHC.
[74] C. Mulrow,et al. Current methods of the US Preventive Services Task Force: a review of the process. , 2001, American journal of preventive medicine.
[75] Finn V. Jensen,et al. Bayesian Networks and Decision Graphs , 2001, Statistics for Engineering and Information Science.
[76] Adrian F. M. Smith,et al. Evidence-based medicine as Bayesian decision-making. , 2000, Statistics in medicine.
[77] D. Hensher,et al. Stated Choice Methods: Analysis and Applications , 2000 .
[78] A. McAlearney,et al. Quality-adjusted life-years and other health indices: a comparative analysis. , 1999, Clinical therapeutics.
[79] C Cates,et al. Confidence intervals for the number needed to treat , 1999 .
[80] G H Guyatt,et al. Users' guides to the medical literature: XVI. How to use a treatment recommendation. Evidence-Based Medicine Working Group and the Cochrane Applicability Methods Working Group. , 1999, JAMA.
[81] J Beckmann. Basic aspects of risk-benefit analysis. , 1999, Seminars in thrombosis and hemostasis.
[82] W. Ried,et al. QALYs versus HYEs--what's right and what's wrong. A review of the controversy. , 1998, Journal of health economics.
[83] Ralph L. Keeney,et al. Book Reviews : Scientific Opportunities and Public Needs: Improv ing Priority Setting and Public Input at the National Institutes of Health. Institute of Medicine. Washington, DC: National Academy Press, 1998, 136 pages, $26.00 , 1998 .
[84] H. Korting,et al. The Benefit/Risk Ratio: A Handbook for the Rational Use of Potentially Hazardous Drugs , 1998 .
[85] Risto Lahdelma,et al. SMAA - Stochastic multiobjective acceptability analysis , 1998, Eur. J. Oper. Res..
[86] M Ryan,et al. Using conjoint analysis to assess women's preferences for miscarriage management. , 1997, Health economics.
[87] K A Schulman,et al. Mathematical Models in Decision Analysis , 1997, Infection Control & Hospital Epidemiology.
[88] M. Schulzer,et al. 'Unqualified success' and 'unmitigated failure': number-needed-to-treat-related concepts for assessing treatment efficacy in the presence of treatment-induced adverse events. , 1996, International journal of epidemiology.
[89] R. Gelber,et al. Comparing Treatments Using Quality-Adjusted Survival: The Q-TWiST Method , 1995 .
[90] C Chuang-Stein,et al. A new proposal for benefit-less-risk analysis in clinical trials. , 1994, Controlled clinical trials.
[91] R. Riegelman,et al. Adjusting the Number Needed to Treat , 1993, Medical decision making : an international journal of the Society for Medical Decision Making.
[92] E. Chelimsky,et al. Cross-design Synthesis: A New Form of Meta-analysis for Combining Results from Randomized Clinical Trials and Medical-practice Databases , 1993, International Journal of Technology Assessment in Health Care.
[93] H Raiffa,et al. Decision Analysis: Introductory Lectures on Choices under Uncertainty. , 1969 .
[94] C Chuang-Stein,et al. Three measures for simultaneously evaluating benefits and risks using categorical data from clinical trials. , 1991, Statistics in medicine.
[95] A. Fletcher. Pressure to treat and pressure to cost: a review of cost-effectiveness analysis. , 1991, Journal of hypertension.
[96] Judea Pearl,et al. Probabilistic reasoning in intelligent systems - networks of plausible inference , 1991, Morgan Kaufmann series in representation and reasoning.
[97] David M. Eddy,et al. The Confidence Profile Method: A Bayesian Method for Assessing Health Technologies , 1989, Oper. Res..
[98] Robert Cameron Mitchell,et al. Using Surveys to Value Public Goods: The Contingent Valuation Method , 1989 .
[99] P Glasziou,et al. Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[100] D L Sackett,et al. An assessment of clinically useful measures of the consequences of treatment. , 1988, The New England journal of medicine.
[101] D M Eddy,et al. The value of mammography screening in women under age 50 years. , 1988, JAMA.
[102] G. Carrin. Economic evaluation of health care interventions: a review of alternative methods. , 1984, Social science & medicine.
[103] R. L. Keeney,et al. Decisions with Multiple Objectives: Preferences and Value Trade-Offs , 1977, IEEE Transactions on Systems, Man, and Cybernetics.
[104] J. Linnerooth,et al. The value of human life: a review of the models. , 1979, Economic inquiry.
[105] John B. Kidd,et al. Decisions with Multiple Objectives—Preferences and Value Tradeoffs , 1977 .
[106] Payne Jt,et al. A survey of the benefits and risks in the practice of radiology. , 1975 .
[107] J. Payne,et al. A survey of the benefits and risks in the practice of radiology. , 1975, CRC critical reviews in clinical radiology and nuclear medicine.